The Abbott nutrition business spin-off was announced on 21 October 2026: Abbott Laboratories intends to separate its nutrition division, which includes Similac, PediaSure, Pedialyte, Glucerna and Ensure, into an independent publicly traded company by the end of 2027. Abbott says the division has about $8.5 billion in annual sales. It is an announced plan, not a completed transaction, and it remains subject to regulatory approvals, an effective registration statement and final board approval. On the same day Abbott said it now expects 2026 comparable sales growth of about 6%, down from a range of 6.5% to 7.5%. This report separates what is confirmed from what is open. It is general information and not investment advice.
Abbott nutrition business spin-off: key takeaways
- Abbott intends to distribute shares of a new nutrition company to its shareholders, who would then own shares in both companies.
- Completion is expected by the end of 2027, subject to regulatory approvals, an effective Form 10 registration statement and final board approval.
- Abbott says the separation is intended to be tax-free for US federal income tax purposes and that the combined dividends of the two companies are expected to equal Abbott’s dividend at the time.
- Abbott lowered its 2026 comparable sales growth outlook to about 6% and narrowed adjusted earnings guidance to $5.50 to $5.55 a share, keeping the midpoint.
- Abbott says the separation will not affect its 2026 guidance; one-time charges are expected but have not been sized.
What Abbott announced about the nutrition business spin-off
According to Abbott’s announcement of 21 October 2026, the nutrition company would have about 16,000 employees and 14 manufacturing sites. Daniel Salvadori, currently group president of established pharmaceuticals and nutritional products, will become its chief executive. Abbott says the nutrition business will keep operating as part of Abbott until the separation. Abbott would retain about $42 billion in sales and about 106,000 employees, concentrated in medical devices, diagnostics and established medicines. Goldman Sachs is financial adviser and Wachtell, Lipton, Rosen & Katz is legal counsel.
How the Abbott nutrition business spin-off would work
General background: in a spin-off, a parent company distributes shares of a subsidiary to its own shareholders, usually in proportion to their holdings, and the subsidiary then trades separately. Unlike a sale, the parent does not receive cash from a buyer. The new company normally files a registration statement, called a Form 10 in the United States, with the US Securities and Exchange Commission, setting out its finances, risks and how debt, assets and liabilities are divided. Shareholders generally do not choose to take part; they receive the new shares.
The timeline for the Abbott nutrition business spin-off
Abbott gives the end of 2027 as the expected completion date. Between now and then the company has to prepare the Form 10, obtain regulatory approvals and receive final approval from its board. A date given more than a year ahead is a target and can change. Nothing has been distributed, no listing venue or ticker has been named in what we reviewed, and the company has not said what the new company will be called.
The strategic rationale for the Abbott nutrition business spin-off
Abbott chairman and chief executive Robert Ford said the separation will benefit both companies and that nutrition will be better positioned as an independent company, leaving Abbott with a core, higher-growth portfolio of medical devices, diagnostics and established medicines. These are the company’s statements. Analysts quoted in market coverage described the logic as clear, and one noted that nutrition has at times weighed on total sales growth, that its margins are below the company average and that infant formula litigation remains an overhang. Those are analyst opinions.
The 2026 outlook change beside the Abbott nutrition business spin-off
Abbott said it now expects 2026 comparable sales growth of about 6%, compared with its previous range of 6.5% to 7.5%. Our calculation puts the midpoint of the old range at 7.0%, so the new figure is about one percentage point lower. Abbott kept the midpoint of its adjusted earnings guidance and narrowed the range to $5.50 to $5.55 from $5.45 to $5.60, according to market coverage. The release we reviewed attributes the quarter to balanced growth across the portfolio and gives no single reason for the lower sales outlook, so we do not assign one.
How the nutrition business has performed
In its third-quarter results filing, Abbott reported nutrition sales of $2.262 billion, up 4.9% on a comparable basis, with pediatric sales up 8.8% as reported and adult up 2.0%. That is about 17% of the company’s $13.0 billion quarterly sales by our calculation. One third-party analysis says nutrition comparable sales fell 2.1% over the first nine months and that US sales fell 4.5%; we have not verified those figures. Taken together they suggest the third quarter was better than the year to date.
What is not yet known about the Abbott nutrition business spin-off
- Where the new company will list, its name and its capital structure.
- How debt, cash and legal liabilities will be divided between the two companies.
- The size of the one-time charges Abbott expects before the separation.
- Abbott’s guidance for 2027, which the company says it expects to give in January.
Litigation and the Form 10 for the Abbott nutrition business spin-off
Market coverage notes that Abbott agreed in September to a $385 million settlement with the US Department of Justice over claims linked to the 2022 infant formula recall, and in August to resolve part of the litigation over preterm infant formulas, with about $670 million paid in aggregate; Abbott says neither is an admission of liability. Mr Ford said unresolved legal matters are not a precondition for completing the separation. Which company will carry any remaining liabilities has not been disclosed, and the registration statement is where that division should appear.
Risks and caveats on the Abbott nutrition business spin-off
- The spin-off is a plan and can be delayed, changed or cancelled.
- Tax-free treatment is Abbott’s intention and not a guarantee.
- Litigation allocation is undisclosed.
- This is news reporting, not investment advice.
In our assessment, the Abbott nutrition business spin-off makes sense as a simplification, but whether it creates value depends on details not yet published, especially liabilities, margins and capital structure. More in our healthcare services coverage.
What to watch next on the Abbott nutrition business spin-off
- The Form 10 filing and what it says about liabilities and finances.
- Abbott’s 2027 guidance in January, available through Abbott.
- Any change to the end-2027 timing.
Frequently asked questions
What is Abbott spinning off?
Its nutrition business, including Similac, PediaSure, Pedialyte, Glucerna and Ensure, with about $8.5 billion in annual sales according to Abbott.
When will the spin-off happen?
Abbott expects it by the end of 2027, subject to approvals and conditions.
Will Abbott shareholders get shares in the new company?
Yes, Abbott says shareholders will own shares in both companies after a distribution.
How we reported this: we relied on Abbott’s announcement and its third-quarter results filing, market coverage of 21 October 2026 and third-party analysis, which are labelled. Our calculations are labelled. Last updated: 23 October 2026. This article is news reporting and not investment advice.